I've followed Dendreon and Oncothyreon among others for around 8+ months now and although I realize that biotechs outside the US don't get the attention in the media that US based biotechs do, I am truly surprised that not many people have even heard about Prima Biomed (ASX.PRR), a little biotech in Australia (let alone make the link between them.

Prima Biomed has just received FDA approval to begin phase IIb/III trials of its headline drug CVac, an "ex vivo" Ovarian cancer vaccine that looks to be incredibly promising and has enormous market potential if it gets to market. It's by far the closest new drug to treat this cancer in the world and uses the same method as Dendreon for the treatment of patients blood (ex vivo).

This stock is incredibly undervalued by any biotech's standard and one would think should see huge price gains in the coming months as it moves steadily toward successful completion of trials and then commercialization. Once finally approved, CVac can then be used to treat all sorts of cancers without further approvals. This is a gem that is going to have a very large boot to kick some market booty when it matures over the next couple of years.

Whilst PRR is not yet listed on the NASDAQ, don't be put off by the fact that you'd have to have AUD$ funds available for this. The AUD$ is set to strenthen against many currencies including the USD$.

I should state that there is no official relationship between Dendreon and Prima. They share the same technique, however they are not really in competition. Prima's patents prevent Dendreon from target the same cancer cell protein (Mucin-1) and Prima also has freedom to target the same protein on a wide variety of cancers (and there are many). Note: these are the only 2 companies in the entire world that use this ex-vivo technique of extracting the patient's blood, treating (training the cells) and reentering the body to boost the patient's own immune system.

http://www.skynews.com.au/podcast/feeds/SkyNewsPodcast_YourMoneyYourCall_20090820153750.mp3

Be patient when listening to the analyst report . Somewhere around 11m into the mp3. It's worth finding.

planet